510(k)

K211648: Diazyme Human Kappa Free Light Chain Assay, Diazyme Human Lambda Free Light Chain Assay

FDA 510(k) · Diazyme Laboratories, Inc. · decided Sep 8, 2022

Key facts

510(k) number K211648
Device name Diazyme Human Kappa Free Light Chain Assay, Diazyme Human Lambda Free Light Chain Assay
Applicant Diazyme Laboratories, Inc.
Product code DFH
Subsequent product codes DEH
Date received May 28, 2021
Decision date Sep 8, 2022
Decision Substantially equivalent (SESE)
Submission type Traditional
Review panel Immunology
Medical specialty Immunology

At a glance

  • None MAUDE adverse event reports
  • None Recall events
  • None UDI device identifiers (GUDID)
  • 1–9 Predicate devices cited
  • 1–9 Later submissions citing this device
  • 10–99 510(k)s with this product code
  • No 510(k) summary on file
  • Yes 510(k) statement on file
  • Not listed On the FDA AI-enabled device list

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

Reading a 510(k)

Decision
SESE means the FDA found the device substantially equivalent to its predicate, so it may be marketed in the United States.
Predicates
Each clearance cites one or more legally marketed devices; the chain of predicates shows where a technology came from.
Product code
The three-letter code sets the device type, class and regulation, and groups competing clearances.
Summary or statement
Applicants file either a 510(k) summary of the safety and effectiveness information or a statement that it is available on request.

About 510(k) premarket notifications

A 510(k) is a premarket submission made to the FDA to demonstrate that a device is substantially equivalent to a legally marketed predicate device.

Source: U.S. Food and Drug Administration (FDA), 510(k) Premarket Notification database · Source date:

Browse all 510(k) premarket notifications